On 24 April 2015, orphan designation (EU/3/15/1486) was granted by the European Commission to Clinipace GmbH, Germany, for recombinant human mesencephalic astrocyte-derived neurotrophic factor for the treatment of retinitis pigmentosa.
The sponsorship was transferred to Amarantus Europe Limited, United Kingdom in September 2016 and subsequently to RegIntel Limited, Ireland, in November 2016.
Recombinant human mesencephalic astrocyte-derived neurotrophic factor
Treatment of retinitis pigmentosa
|Orphan designation status||
|EU designation number||
|Date of designation||
Review of designation
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: